Viral infection is a continuing threat to mankind and drug resistance to available antivirals has appeared in an alarming rate. There is an urgent need to identify new druggable targets and find new antiviral drugs in light of rapid emerging and re-emerging viral pathogens. Our first success in applying forward chemical genetics in the identification of biologically active small molecule inhibitors of SARS-CoV in 2004 (Kao et al., Chemistry & Biology, 11:1293) has prompted us to tackle influenza A virus pathogenesis using this novel approach. Applying the concept of chemical genetics, after screening a validated high quality chemical library (50,240 structurally diverse small molecules) with an automated robotic platform for high-throughput screening (HTS), we have identified more than 1000 small-molecule inhibitors that will inhibit the infectivity of the viruses in Madin-Darby canine kidney (MDCK) cell-based HTS assay. Subsequent secondary screening and hit validation processes identified 39 potent antiviral compounds interfering with influenza A infection. We further identified compounds that perturbed intracellular trafficking of the viral nucleoprotein (NP) and characterized a compound (nucleozin) that apparently stopped the nuclear localization of the NP (Kao et al., Nature Biotechnology 28:600). The binding site of compound nucleozin was mapped to residue Y289 of NP. Balb-c mice treated by nucleozin were significantly protected after infection by a hypervirulent strain of influenza A H5N1/Vietnam/1194/04, illustrating the *in vivo* efficacy of nucleozin in inhibiting H5N1 infection. Further investigation using immunofluorescence techniques and gel-shift assays illustrated that nucleozin induced a time-dependent and RNA enhanced specific aggregation of NP. Our results demonstrated that chemical genetics is an attractive approach for the identification of druggable targets, new antiviral drugs, and novel antiviral mechanisms.
